Drug intelligence / Profile preview

HET0016

Development stage
Preclinical
Lead developer
Augusta University
Modality
Small Molecules
Administration
Intravenous, Intraperitoneal
01

Overview

HET0016 (N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine) is a potent and selective small molecule inhibitor of 20-hydroxyeicosatetraenoic acid (20-HETE) synthesis. It primarily acts by inhibiting enzymes in the cytochrome P450 4A (CYP4A) and 4F (CYP4F) families, which are responsible for the omega-oxidation of arachidonic acid to 20-HETE. 20-HETE is a bioactive lipid that plays a significant role in promoting tumor cell proliferation, migration, and neovascularization. In preclinical studies, HET0016 has been shown to reduce tumor aggressiveness, inhibit angiogenesis, and disrupt vascular mimicry in models of glioblastoma and triple-negative breast cancer. It also appears to modulate the IL-8/CXCR2 signaling pathway, further contributing to its anti-tumor effects.

Other names
N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidineN-hydroxy-N'-(4-butyl-2-methylphenyl)methanimidamide
02

Targets

CYP2C/CYP2J (Cytochrome P450 2C and 2J epoxygenase)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)CYP2D6 (Cytochrome P450 2D6)CYP3A4 (Cytochrome P450 3A4)CYP4A (Cytochrome P450 4A family)CYP4A11 (Cytochrome P450 family 4 subfamily A member 11)CYP4F2 (Cytochrome P450 family 4 subfamily F member 2)CYP4F3COXCYP4F (Cytochrome P450 family 4 subfamily F)

Beyond the preview

Go deeper on HET0016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HET0016.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call